Hot Features
Premium
Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| AcelRX Pharmaceuticals Inc | ACRX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.86 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.86 | 0.86 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.425 - 1.38 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 0.86 | USD |
AcelRX Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 18.82M | 16.95M | - | 651k | -18.4M | -1.09 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
AcelRX Pharmaceuticals News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ACRX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.51 | 0.8775 | 0.425 | 0.6784028 | 123,769 | 0.35 | 68.63% |
| 1 Year | 0.69 | 1.38 | 0.425 | 0.8258216 | 191,384 | 0.17 | 24.64% |
| 3 Years | 25.20 | 33.40 | 0.425 | 12.07 | 987,246 | -24.34 | -96.59% |
| 5 Years | 74.00 | 81.00 | 0.425 | 27.62 | 1,337,232 | -73.14 | -98.84% |
AcelRX Pharmaceuticals Description
| AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its product portfolio includes DSUVIA and Zalviso for Moderate-to-severe acute pain. The company's products under pipeline are ARX-02 and ARX-03. The majority of its revenue is generated from DSUVIA product sales in the United States. |
